Nucleoside/tide analogues (NAs) have long been used in the fight against viral diseases,
and now present a promising option for the treatment of COVID-19. Once activated to the 5 …

Nucleotide analogues (NA) are currently employed for treatment of several viral diseases,
including COVID-19. NA prodrugs are intracellularly activated to the 5′-triphosphate form …

The risk of zoonotic coronavirus spillover into the human population, as highlighted by the
SARS-CoV-2 pandemic, demands the development of pan-coronavirus antivirals. The …

The COVID‐19 pandemic remains a major health concern worldwide, and SARS‐CoV‐2 is
continuously evolving. There is an urgent need to identify new antiviral drugs and develop …

Emerging coronaviruses (CoVs) cause severe disease in humans, but no approved
therapeutics are available. The CoV nsp14 exoribonuclease (ExoN) has complicated …

The absence of 'shovel-ready'anti-coronavirus drugs during vaccine development has
exceedingly worsened the SARS-CoV-2 pandemic. Furthermore, new vaccine-resistant …

Highlights•Coronaviruses (CoV) represent current and future risk for pandemic zoonotic
infections.•Nucleoside analogues are highly active across multiple virus families.•CoVs …

Great pioneers of nucleic acid chemistry had elucidated nucleic acid functions and
structures and developed various antiviral modified nucleoside drugs. It is possible in theory …

Nucleotide analog inhibitors, including broad-spectrum remdesivir and favipiravir, have
shown promise in in vitro assays and some clinical studies for COVID-19 treatment, this …

RNA-dependent RNA polymerase (RdRp), also known as nsp12, is a key component in the
synthesis of viral ribonucleic acid (RNA) and is considered the primary target of nucleoside …